東曜藥業-B(01875.HK)貝伐珠單抗注射液新增適應症補充申請獲批
東曜藥業-B(01875.HK)公布,附屬公司蘇州東曜近日收到國家藥品監督管理局通知,貝伐珠單抗注射液「朴欣汀」新增適應症補充申請已獲核准簽發。包括晚期、轉移性或復發性非鱗狀非小細胞肺癌(nsNSCLC)和轉移性結直腸癌(mCRC),朴欣汀共有5項適應症獲批。
公司預期,此次朴欣汀的新增適應症補充申請獲批准後,將進一步擴大產品市場空間,滿足更多中國癌症患者用藥的可及性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.